KTKenneth S. Thomson

Kenneth S. Thomson

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Kenneth S. Thomson has a total of 42 co-authors. Here are the top co-authors by number of shared publications:

  • Gina K. Thomson

    University of Louisville Hospital, Louisville, Kentucky, USA

    4 shared publications
  • Sameh AbdelGhani

    University of Louisville School of Medicine, Department of Pathology and Laboratory Medicine Louisville, Kentucky, United States of America

    4 shared publications
  • Gina K. Thomson

    Department of Pathology and Laboratory Medicine, School of Medicine, University of Louisville, Louisville, Kentucky, USA

    2 shared publications
  • James W. Snyder

    University of Louisville School of Medicine, Louisville, Kentucky, USA

    2 shared publications
  • Amal Eissa Saafan

    Department of Pharmaceutical Microbiology and Immunology, Faculty of Pharmacy, Beni-Suef University, Beni-Suef, Egypt

    1 shared publication
  • Andrew Deeb

    Department of Medical Microbiology and Immunology, Creighton University School of Medicine, Omaha, Nebraska

    1 shared publication

Latest Publications

  • Rapid identification from rectal swabs of the clinically most relevant carbapenemase genes from gram-negative bacteria using the BD MAX Check-Points CPO Assay

    by Sergio García-Fernández, Patricia J. Simner, Gina Thomson, Matthew Faron, Ron Bosboom, Arjanne van Griethuijsen, María García-Castillo, Renee Harris, Nathan A. Ledeboer, Rafael Cantón, et al.


  • Digital imaging for reading of direct rapid antibiotic susceptibility tests from positive blood cultures

    by Gina K. Thomson, Kira Jamros, James W. Snyder, Kenneth S. Thomson

    Delaying effective antibiotic therapy is a major cause of sepsis-associated mortality. The EUCAST rapid antibiotic susceptibility test (RAST) is performed from positive blood cultures to provide rapid results. Disc diffusion tests inoculated with positive blood culture broth are read at 4, 6, and 8 h and interpreted against species and time-specific criteria. Potential problems are the possibility of missing specific reading times for tests and slower growth in incubators that are frequently opened. The current study aimed to assess if digital visualization by the BD Kiestra™ total laboratory automation system is suitable for reading RASTs by capturing images at the correct times and retaining them for review. Utilizing the Kiestra™ InoqulA, 100 μl of positive blood culture broth was lawn-inoculated onto Mueller-Hinton agar and incubated at 35 °C for automated digital zone measurement at 4, 6, and 8 h. Aliquots from 135 positive blood cultures were tested against EUCAST-recommended and other drugs and assessed for readability of digital images. Microdilution MICs were determined in parallel to RASTs. All isolates except 7/10 enterococci yielded images of suitable quality for zone measurement. Of the 641 digitally read tests for other organisms, 207 (32.3%) were readable in 4 h, 555 (86.6%) in 6 h, and 641 (100%) in 8 h. For tests included in EUCAST criteria, 92.1% provided categorical agreement with microdilution MICs. Digital image reading of RASTs is a potentially viable, inexpensive tool for providing rapid susceptibility results which can help reduce sepsis-associated mortality.


  • Open Access

    CPO Complete, a novel test for fast, accurate phenotypic detection and classification of carbapenemases

    by Gina K Thomson, Sameh AbdelGhani, Kenneth S Thomson

    Carbapenemase-producing organisms (CPOs) are Gram-negative bacteria that are typically resistant to most or all antibiotics and are responsible for a global pandemic of high mortality. Rapid, accurate detection of CPOs and the classification of their carbapenemases are valuable tools for reducing the mortality of the CPO-associated infections, preventing the spread of CPOs, and optimizing use of new β-lactamase inhibitor combinations such as ceftazidime/avibactam, meropenem/vaborbactam and imipenem/relebactam. The current study evaluated the performance of CPO Complete, a novel, manual, phenotypic carbapenemase detection and classification test. The test was evaluated for sensitivity and specificity against 262 CPO isolates of Enterobacteriaceae, Pseudomonas aeruginosa and Acinetobacter baumannii and 67 non-CPO isolates. It was also evaluated for carbapenemase classification accuracy against 205 CPOs that produced a single carbapenemase class. The test exhibited 100% sensitivity 98.5% specificity for carbapenemase detection within 90 minutes and detected 74.1% of carbapenemases within 10 minutes. In the classification evaluation, 99.0% of carbapenemases were correctly classified for isolates that produced a single carbapenemase. The test is technically simple and has potential for adaptation to automated instruments. With lyophilized kit storage at temperatures up to 38°C, the CPO Complete test has the potential to provide rapid, accurate carbapenemase detection and classification in both limited resource and technologically advanced laboratories.


  • Open Access

    CPO Complete, a novel test for fast, accurate phenotypic detection and classification of carbapenemases

    by Gina K. Thomson, Sameh AbdelGhani, Kenneth S. Thomson

    Rapid, accurate detection of carbapenemase-producing organisms (CPOs) and the classification of their carbapenemases are valuable tools for reducing the mortality of the CPO-associated infections, preventing the spread of CPOs, and optimizing use of new β-lactamase inhibitor combinations such as ceftazidime/avibactam and meropenem/vaborbactam. The current study evaluated the performance of CPO Complete, a novel, manual, phenotypic carbapenemase detection and classification test. The test was evaluated for sensitivity and specificity against 262 CPO isolates of Enterobacteriaceae, Pseudomonas aeruginosa and Acinetobacter baumannii and 67 non-CPO isolates. It was also evaluated for carbapenemase classification accuracy against 205 CPOs that produced a single carbapenemase class. The test exhibited 100% sensitivity 98.5% specificity for carbapenemase detection within 90 minutes and detected 74.1% of carbapenemases within 10 minutes. In the classification evaluation, 99.0% of carbapenemases were correctly classified. The test is technically simple and has potential for adaptation to automated instruments. With lyophilized kit storage at temperatures up to 38°C the CPO Complete test has the potential to provide rapid, accurate carbapenemase detection and classification in both limited resource and technologically advanced laboratories.

  • Open Access

    Activity of Cefepime-Zidebactam against Multidrug-Resistant (MDR) Gram-Negative Pathogens

    by Kenneth S. Thomson, Sameh AbdelGhani, James W. Snyder, Gina K. Thomson

    This study compared the activity of cefepime + zidebactam (FEP-ZID) and selected currently available antibacterial agents against a panel of multidrug-resistant (MDR) clinical isolates chosen to provide an extreme challenge for antibacterial activity. FEP–ZID had a very broad and potent in vitro spectrum of activity, and was highly active against many MDR isolates of Enterobacterales, Pseudomonas aeruginosa, and Acinetobacter baumannii. Notably, it inhibited isolates producing carbapenemases of Ambler classes A, B, and D, and P. aeruginosa isolates with multiple resistance mechanisms including combinations of upregulated efflux, diminished or non-functional OprD porins, and AmpC overproduction. Its clinical role will be determined initially by the breakpoints assigned to it, comparison studies with other investigational β-lactamase inhibitor combinations, and ultimately by the developing body of therapeutic outcome data.


  • An Improved Extended-Spectrum-β-Lactamase Detection Test Utilizing Aztreonam plus Clavulanate

    by Gina K. Thomson, Maaz Ayaz, Kelli Lutes, Kenneth S. Thomson

    Clinical laboratories test for ESBLs for epidemiological and infection control purposes and also for potential to cause therapeutic failures with cephalosporins. Testing can be problematic because the CLSI does not recommend testing of all producers of ESBLs and also falsely negative results may occur with isolates that co-produce AmpC. Boronic acid supplemented tests can enhance ESBL detection in AmpC producers. Because aztreonam inhibits AmpCs, a study was designed to compare ESBL detection by the CLSI disk test (CLSI), a boronic acid supplemented CLSI disk test (CLSI + BA), and an aztreonam + clavulanate disk test (ATM + CA). The study tested 100 well-characterized Enterobacteriaceae, Acinetobacter baumannii and Pseudomonas aeruginosa. Seventy produced TEM, SHV or CTX-M ESBLs, with 15 co-producing an AmpC, and 11 co-producing a metallo-β-lactamase. Thirty ESBL-negative isolates were also tested. Tests were inoculated by CLSI methodology and interpreted as positive if an inhibitor caused a zone diameter increase of ≥ 5 mm. The percent of ESBL producers detected were ATM + CA, 95.7%; CLSI + BA, 88.6%, and CLSI, 78.6%. When AmpC was co-produced, the sensitivities of the tests were: ATM + CA, 100%; CLSI + BA, 93.3%; and CLSI, 60%. ATM + CA also detected an ESBL in 90.1% of isolates that co-produced a metallo-β-lactamase. Falsely positive tests occurred only with the CLSI and CLSI + BA tests. Overall, the ATM + CA test detected ESBLs more accurately than the CLSI and CLSI + BA tests, especially with isolates co-producing an AmpC or metallo-β-lactamase.


  • Open Access

    High-Stringency Evaluation of the Automated BD Phoenix CPO Detect and Rapidec Carba NP Tests for Detection and Classification of Carbapenemases

    by Gina Thomson, David Turner, William Brasso, Susan Kircher, Thierry Guillet, Kenneth Thomson

    There is an urgent need for rapid, accurate detection and classification of carbapenemases. The current study evaluated the automated BD Phoenix CPO Detect and the manual bioMérieux Rapidec Carba NP tests for meeting these needs. Both tests were challenged with 294 isolates of Enterobacteriaceae spp., Pseudomonas aeruginosa , and Acinetobacter baumannii chosen to provide extreme diagnostic difficulty. Carbapenemases such as KPC, NMC-A, IMI, SME, NDM, SPM, IMP, VIM, and OXA-23, 40, 48, 58, 72, 181, and 232 were produced by 243 isolates and 51 carbapenemase-negative isolates included porin mutants and producers of extended-spectrum β-lactamases (ESBLs), AmpCs, K1, and broad-spectrum β-lactamases. Both tests exhibited high sensitivity of carbapenemase detection (>97%). Due to the highly challenging carbapenemase-negative isolates, specificities were lower than typical for evaluations involving mostly routine clinical isolates. BD Phoenix CPO Detect was 68.6% specific and Rapidec Carba NP was 60.8% to 78.4% specific, depending on how borderline results were interpreted. Only BD Phoenix CPO Detect classified carbapenemases. It correctly classified 85.0% of class A, 72.4% of class B, and 88.6% of class D carbapenemases. Importantly with respect to empirical therapy with new β-lactamase inhibitor combinations such as ceftazidime/avibactam, no class B carbapenemases were misclassified as class A carbapenemases. Both tests offer advantages. Used alone, without initial susceptibility tests, Rapidec Carba NP can provide positive results for some isolates after only 10 to 30 min incubation. BD Phoenix CPO Detect provides novel advantages such as automated carbapenemase detection, inclusion in susceptibility panels to eliminate delays and subjectivity in initiating carbapenemase tests, and classification of most carbapenemases.


  • The Immaculate Carbapenemase Study

    by Kenneth S. Thomson

    Carbapenemase-producing organisms, or CPOs, are Gram-negative pathogens that produce a transmissible carbapenemase and are typically resistant to most (sometimes all) antibiotics. We now face a global CPO pandemic of high mortality. In this issue of the Journal of Clinical Microbiology , Karlowsky et al. (J Clin Microbiol 55:1638–1649, 2017, https://doi.org/10.1128/JCM.02316-16 ) report the results of an extensive global surveillance study that provide much-needed information that enhances our understanding of carbapenemase-producing Enterobacteriaceae (CPE) and which will be valuable for the development of improved strategies for CPE control and therapy of infections.


  • Open Access

    Indirect Tris-EDTA Disk Testing Using Imipenem and Meropenem for Detection of OXA-48 Carbapenemase Production

    by Gina K. Thomson, Sameh AbdelGhani, James W. Snyder, Kenneth S. Thomson

    Enterobacteriaceae producing Class D OXA-48 and OXA-48-like carbapenemases are an increasing concern.…